Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists on Residual Renal Function Preservation in Peritoneal Dialysis Patients

Volume 1 - Issue 4

Reyes Marin Fernando Arturo*

Received: January 19, 2019;   Published: January 24, 2019

DOI: 10.32474/JUNS.2019.01.000117

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) are recommended in peritoneal dialysis (PD) patients for hypertension or heart failure control [1] Angiotensin II (AII) is an important factor in the development of renal fibrosis due to its hemodynamic effects on glomeruli and stimulation of extracellular matrix proteins synthesis, mediated by TGF b [2]. This may explain why treatment with ACEi and ARBs is renoprotective in patients with diabetic and non-diabetic nephropathy [3,4].

Abstract| Introduction| Material and Methods| Results| Discussion| Conclusion| Declaration| References|